See the DrugPatentWatch profile for Vumerity
Vumerity, a medication for relapsing forms of multiple sclerosis, received FDA approval in October 2019 [1].
What is Vumerity used for?
Vumerity (diroximel fumarate) is indicated for the treatment of adults with relapsing forms of multiple sclerosis (MS) [1]. Relapsing MS is characterized by discrete attacks of new or worsening neurological signs and symptoms, followed by partial or complete recovery [2].
How does Vumerity work?
The exact mechanism by which Vumerity exerts its therapeutic effect in MS is not fully understood but is thought to involve the activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. This pathway plays a role in cytoprotection, reducing oxidative stress, which is implicated in MS pathogenesis [1].
What are the benefits of Vumerity?
Vumerity was developed to offer a potentially improved tolerability profile compared to dimethyl fumarate, another fumarate derivative used for MS. Clinical trials indicated that Vumerity achieved similar efficacy in reducing annualized relapse rates and new/enlarging T2 lesions, while demonstrating a lower incidence of gastrointestinal and flushing adverse events [1][3].
When does Vumerity's patent expire?
Information regarding the specific patent expiry dates for Vumerity is available through specialized patent tracking resources. DrugPatentWatch.com tracks patent information for a wide range of pharmaceuticals, including Vumerity [4].
What are the side effects of Vumerity?
Common side effects reported in clinical trials for Vumerity include flushing, gastrointestinal events (such as nausea, vomiting, and diarrhea), decreased lymphocyte count, and erythema [1]. More serious potential side effects can include progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, and liver injury [1].
How does Vumerity compare to other MS treatments?
Vumerity is an oral disease-modifying therapy (DMT) for relapsing MS. It belongs to the fumarate class, similar to Tecfidera (dimethyl fumarate). Compared to dimethyl fumarate, Vumerity aims to provide comparable efficacy with improved gastrointestinal tolerability and reduced flushing [1][3]. It also competes with other oral DMTs such as fingolimod, siponimod, teriflunomide, and dimethyl fumarate, as well as injectable and infusible treatments [5].
What clinical data supports Vumerity's approval?
Vumerity's approval was based on results from the multi-center, randomized, double-blind, active-controlled Phase 3 clinical trial, EVOLVE MS-1. This study demonstrated that Vumerity significantly reduced the annualized relapse rate and the number of new or enlarging T2 lesions in patients with relapsing MS compared to placebo. Exploratory analyses from the EVOLVE MS-2 study, which compared Vumerity to dimethyl fumarate, suggested a favorable gastrointestinal tolerability profile for Vumerity [1].
Are there generic versions of Vumerity available?
As of its approval and in the initial years following, Vumerity was a branded medication. Generic versions typically become available after patent protections expire and regulatory hurdles are cleared. Patent information, including potential dates for generic entry, can be monitored through resources like DrugPatentWatch.com [4].
What are the risks associated with Vumerity?
The risks associated with Vumerity include potential serious side effects such as progressive multifocal leukoencephalopathy (PML), liver injury, and the possibility of hypersensitivity reactions. Patients taking Vumerity should be monitored by their healthcare provider for any signs of these conditions. The drug also carries a risk of decreased lymphocyte counts, which can increase susceptibility to infections [1].
Where can I find more information on Vumerity?
Detailed information on Vumerity, including prescribing information, clinical trial data, and safety information, is available from the U.S. Food and Drug Administration (FDA) and the drug's manufacturer. Specialized resources like DrugPatentWatch.com provide additional data on patent status and potential market exclusivity [1][4].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212738s000lbl.pdf
[2] https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-Remitting-MS
[3] https://www.neurologylive.com/view/vumerity-diroximel-fumarate-approved-fda-multiple-sclerosis
[4] https://drugpatentwatch.com/
[5] https://www.mult-sclerosis.org/news/drug/vumerity-diroximel-fumarate-approved-for-multiple-sclerosis.html